AMPK (5′ AMP-activated protein kinase or 5′ adenosine monophosphate-activated protein kinase) is a key downstream component of a tumor suppressor, LKB1, while mutations of LKB1 are found in over 20% of patients with NSCLC (non-small-cell lung cancer) and frequently associated with activating K-RAS mutations [57–59]. Here, STK11 is linked to non-small cell lung carcinoma.